BEATW — HeartBeam, Inc.

HeartBeam, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $21 million for the full year 2025, equating to $0.62 per share; Q4 net loss was $5.3 million or $0.15 per share, in line with expectations.
• Operating Cash Flow: Less than $14 million for the full year; Q4 cash used in operations was $2.9 million, a 30% decrease year-over-year.
• Cash Position: Cash and cash equivalents totaled $4.4 million as of December 31, 2025.
• Cost Structure: Projected gross operating cash outflows for 2026 expected to be between $17 million and $19 million, with a focus on maintaining a lean operational model.

2. Strategic Updates and Business Highlights

• FDA Clearances: Achieved 510(k) clearance for the 12-lead synthesis software in December 2025, enabling a limited commercial launch.
• Product Launch: Initial focus on concierge and preventive cardiology practices, targeting high-net-worth individuals who are willing to pay for advanced health technology.
• Commercial Strategy: Plans to partner with a small number of practices initially to validate the product's value proposition, with a goal of achieving cash flow breakeven at around 30,000 patients.
• New Product Development: Unveiled a working prototype of an on-demand 12-lead ECG patch, aimed at disrupting the $2 billion ambulatory cardiac monitoring market.
• AI Initiatives: Announced a collaboration with Mount Sinai to develop AI algorithms for heart attack detection and other clinical applications.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipated continued focus on commercialization with a disciplined approach to scaling operations. The company aims to validate its model in the concierge market before expanding further.
• Clinical Studies: Enrollment in the ALIGN ACS pilot study is underway, expected to complete by the end of Q3 2026, which will inform future pivotal studies for heart attack detection.
• Market Expansion: Plans to eventually expand into broader patient-pay segments, including telehealth networks and national healthcare organizations.

4. Challenges and Points of Concern

• Regulatory Uncertainty: While the patch is likely to follow a 510(k) pathway, the regulatory path for heart attack detection remains uncertain, which could impact timelines.
• Market Competition: The company faces competition from existing cardiac monitoring solutions and must demonstrate clear advantages to capture market share.
• Financial Sustainability: While the current cash position is stable, the company must manage its burn rate effectively as it scales operations and invests in new product development.

5. Notable Q&A Insights

• Pilot Study Timeline: The ALIGN ACS study is expected to enroll quickly due to its design, with results anticipated by the end of Q3 2026.
• Commercialization Strategy: Emphasis on deep adoption within a limited number of practices before scaling to larger markets; initial accounts are expected to validate the business model.
• Partnership Opportunities: Interest in exploring additional partnerships with other healthcare providers and institutions to enhance product reach and capabilities.
• Reimbursement Strategy: The company does not plan to rely on immediate reimbursement codes for its initial offerings, focusing instead on patient-pay models, with future reimbursement pathways as a secondary goal.

Overall, HeartBeam, Inc. is positioned for a pivotal year in 2026, with significant developments in product offerings and commercialization strategies, while also navigating regulatory and competitive challenges.